A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden.
Rebeck ON, Wallace MJ, Prusa J, Ning J, Evbuomwan EM, Rengarajan S, Habimana-Griffin L, Kwak S, Zahrah D, Tung J, Liao J, Mahmud B, Fishbein SRS, Ramirez Tovar ES, Mehta R, Wang B, Gorelik MG, Helmink BA, Dantas G
Cell Chem Biol. 2024 Nov 16:S2451-9456(24)00452-5. doi: 10.1016/j.chembiol.2024.10.013.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 226715 | pET28b(+)_rPD-L1nb | Heterologous expression and purification of recombinant PD-L1 nanobody (rPD-L1nb) |
| 226716 | pOGS539_haPD-1 | Plasmid enabling yeast-mediated expression and secretion of high affinity PD-1 microbody (haPD-1) |
| 226717 | pOGS539_rPD-L1nb | Plasmid enabling yeast-mediated expression and secretion of recombinant PD-L1 nanobody (rPD-L1nb) |
| 226718 | pOGS539_GLuc | Plasmid enabling yeast-mediated expression and secretion of Gaussia luciferase (GLuc) |
| 226719 | pOGS539_GLuc-ns | Plasmid enabling yeast-mediated expression of Gaussia luciferase (GLuc) |